Krystal Biotech
KRYS
135 hedge funds and large institutions have $1.37B invested in Krystal Biotech in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 49 reducing their positions, and 26 closing their positions.
78% more call options, than puts
Call options by funds: $5.51M | Put options by funds: $3.1M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4.18% more ownership
Funds ownership: 77.52% → 81.7% (+4.2%)
8% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 49
1% more capital invested
Capital invested by funds: $1.35B → $1.37B (+$15.4M)
4% less funds holding
Funds holding: 140 → 135 (-5)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$33.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$22.9M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$9.93M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$53.9M |
| 2 |
AG
Artal Group
Luxembourg
|
-$12.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.48M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$7.59M |
| 5 |
Millennium Management
New York
|
-$3.83M |
KRYS Hedge Fund Activity: Q1 2022 in Review
135 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2022, worth a combined $1.37B — up 1.1% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KRYS and 22 opened new positions — a net loss of 4 holders — while 49 trimmed existing stakes and 53 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $33.1M. The largest seller was Frazier Management, exiting entirely with an estimated $53.9M sold.
- 135 institutional investors held Krystal Biotech (KRYS) as of Q1 2022, down from 140 in Q4 2021.
- Funds reported $1.37B of Krystal Biotech stock for Q1 2022, up 1.1% quarter-over-quarter.
- 22 funds opened new Krystal Biotech positions in Q1 2022 and 26 closed out, a net change of -4 holders.
- The largest Krystal Biotech buyer in Q1 2022 was Avoro Capital Advisors, an estimated $33.1M added.
- The largest Krystal Biotech seller in Q1 2022 was Frazier Management, an estimated $53.9M sold.
Based on aggregated 13F filings for Q1 2022.